This is a summary of the European public assessment report (EPAR) for Constella. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Constella.
Therapeutic Indication
### Therapeutic indication Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.
Therapeutic Area (MeSH)
ATC Code
A06AX04
ATC Item
linaclotide
Pharmacotherapeutic Group
Drugs for constipation
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| linaclotide | N/A | 利那洛肽 |
EMA Name
Constella
Medicine Name
Constella
Aliases
N/ANo risk management plan link.
